HMPL 760
Alternative Names: HMPL-760Latest Information Update: 28 Apr 2025
At a glance
- Originator HUTCHMED
- Class Antineoplastics; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Diffuse large B cell lymphoma
- Phase I Non-Hodgkin's lymphoma
- No development reported Chronic lymphocytic leukaemia
Most Recent Events
- 09 Apr 2025 Phase I development in Non-Hodgkin's lymphoma (Second-line therapy or greater) in China is still ongoing (PO) (NCT05190068)
- 28 Feb 2025 No recent reports of development identified for phase-I development in Chronic-lymphocytic-leukaemia(Second-line therapy or greater) in China (PO)
- 28 Feb 2025 No recent reports of development identified for phase-I development in Chronic-lymphocytic-leukaemia(Second-line therapy or greater) in USA (PO)